NDA 18009, held by Procter And Gamble. Saralasin Acetate.
As of Nov 13, 2026, NDA 18009 (Sarenin), held by Procter And Gamble, was not approved, with 0 approved supplements and 0 published complete response letters.
| Product | Active ingredient | Marketing |
|---|---|---|
| SareninEQ 0.6MG BASE/ML ยท injectable;injection | Saralasin Acetate | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
